• 1
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 15411549.
  • 2
    Blonski W, Lichtenstein GR. Safety of biologic therapy. Inflamm Bowel Dis. 2007; 13: 769796.
  • 3
    Canin-Endres J, Salky B, Gattorno F, et al. Laparoscopically assisted intestinal resection in 88 patients with Crohn's disease. Surg Endosc. 1999; 13: 595599.
  • 4
    Mekhjian HS, Switz DM, Watts HD, et al. National cooperative Crohn's disease study: factors determining recurrence of Crohn's disease after surgery. Gastroenterology. 1979; 77( 4 Pt 2): 907913.
  • 5
    Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001; 49: 777782.
  • 6
    Lewis RT, Maron DJ. Efficacy and complications of surgery for Crohn's disease. Gastroenterol Hepatol. 2010; 6: 587596.
  • 7
    Yamamoto T, Keighley MR. Factors affecting the incidence of postoperative septic complications and recurrence after strictureplasty for jejunoileal Crohn's disease. Am J Surg. 1999; 178: 240245.
  • 8
    Dietz DW, Laureti S, Strong SA, et al. Safety and longterm efficacy of strictureplasty in 314 patients with obstructing small bowel Crohn's disease. J Am Coll Surg. 2001; 192: 330337.
  • 9
    Broering DC, Eisenberger CF, Koch A, et al. Strictureplasty for large bowel stenosis in Crohn's disease: quality of life after surgical therapy. Int J Colorectal Dis. 2001; 16: 8187.
  • 10
    Tichansky D, Cajir B, Yoo E, et al. Strictureplasy for Crohn's disease: metaanalysis. Dis Colon Rectum. 2000; 43: 911919.
  • 11
    Yang Z, Wu Q, Wu K, et al. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther. 2010; 31: 486492
  • 12
    Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomised studies in meta-analyses. Available at
  • 13
    Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557560.
  • 14
    Tay GS, Binion DG, Eastwood D, et al. Multivariate analysis suggests improved perioperative outcome in Crohn's disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery. 2003; 134: 565572.
  • 15
    Marchal L, D'Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther. 2004; 19: 749754.
  • 16
    Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004; 99: 878883.
    Direct Link:
  • 17
    Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg. 2008; 12: 17381744.
  • 18
    Indar AA, Young-Fadok TM, Heppell J, et al. Effect of perioperative immunosuppressive medication on early outcome in Crohn's disease patients. World J Surg. 2009; 33: 10491052.
  • 19
    Canedo J, Lee SH, Pinto R, Murad-Regadas S, et al. Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates? Colorectal Dis. 2011; 13: 12941298.
  • 20
    Nasir BS, Dozois EJ, Cima RR, et al. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. J Gastrointest Surg. 2010; 14: 18591865.
  • 21
    Kasparek MS, Bruckmeier A, Beigel F, et al. Infliximab does not affect postoperative complication rates in Crohn's patients undergoing abdominal surgery. Inflamm Bowel Dis. 2011 [Epub ahead of print].
  • 22
    Kunitake H, Hodin R, Shellito PC, et al. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg. 2008; 12: 17301736.
  • 23
    Rizzo G, Armuzzi A, Pugliese D, et al. Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. Int J Colorectal Dis. 2011; 26: 14351444.
  • 24
    Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007; 46: 645660.
  • 25
    Busti AJ, Hooper JS, Amaya CJ, et al. Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing. Pharmacotherapy. 2005; 25: 15661591.
  • 26
    Mooney DP, O'Reilly M, Gamelli RL. Tumor necrosis factor and wound healing. Ann Surg. 1990; 211: 124129.
  • 27
    Lee, R, Efron DT, Udaya T, et al. Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats. Wound Repair Regen. 2000; 8: 547553.
  • 28
    Rapala KT, Vaha-Kreula MO, Heino JJ, et al. Tumor necrosis factor-alpha inhibits collagen synthesis in human and rat granulation tissue fibroblasts. Experientia. 1996; 52: 7076.
  • 29
    Talwalkar SC, Grennan DM, Gray J, et al. Tumor necrosis factor antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis. 2005; 64: 650651.
  • 30
    Wendling D, Balblanc J-C, Brousse A, et al. Surgery in patients receiving anti-tumour necrosis factor a treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis. 2005; 64: 13781379.
  • 31
    den Broeder AA. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol. 2007; 34: 689695.
  • 32
    Kawakami K, Ikari K, Kawamura K. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology (Oxford). 2010; 49: 341347.
  • 33
    Hession M, Gottlieb A. Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders. J Dermatol Treat. 2011; 22: 90101.
  • 34
    Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-α inhibition therapy. Foot Ankle Int. 2004; 25: 331335.
  • 35
    Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007; 204: 956962.
  • 36
    Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum. 2007; 50: 17471753.
  • 37
    Mor IJ, Vogel JD, da Luz Moreira A, et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum. 2008; 51: 12021207.
  • 38
    Ferrante M, D'Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis. 2009; 15: 10621070.
  • 39
    Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005; 128: 18051811.
  • 40
    Subramanian V, Pollok RC, Kang JY, et al. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg. 2006; 93: 793799.
  • 41
    Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006; 4: 621630.
  • 42
    D'Haens G, Colombel JF, Hommes DW, et al. Corticosteroids pose an increased risk for serious infection: an interim safety analysis of the ENCORE registry. Gastroenterology. 2008; 134: A140.